-
Novartis Pharmaceuticals Corporation et al v. West-Ward Pharmaceuticals International-Limited DC CAFC
- 1:14-cv-01196
- D. Del.
- Judge: Richard G. Andrews
- Filed: 09/16/2014
- Closed: 03/14/2019
- Latest Docket Entry: 03/18/2019
- PACER
- Docket updated daily
2
Plaintiffs
2
Defendants
1
Accused
Product
4
Patents-in-Suit
1,641
Days in
Litigation
-
Novartis Pharmaceuticals Corporation et al v. West-Ward Pharmaceuticals International-Limited DC CAFC
- 1:14-cv-01196
- D. Del.
- Judge: Richard G. Andrews
- Filed: 09/16/2014
- Closed: 03/14/2019
- Latest Docket Entry: 03/18/2019
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
7 |
A method of treating or preventing an autoimmune or inflammatory condition or transplant rejection in a subject suffering from or at risk for such condition or rejection, comprising co-administering synergistically effective amounts of (I) an IL-2
view more
|
Valid
Entry 169 |
Claim # | Claim Text | Outcome |
---|---|---|
7 |
A method of treating or preventing an autoimmune or inflammatory condition or transplant rejection in a subject suffering from or at risk for such condition or rejection, comprising co-administering synergistically effective amounts of (I)
view more
|
Invalid (101 and 103)
Entry 120 |
Claim # | Claim Text | Outcome |
---|---|---|
7 |
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier therefor.
|
Invalid (101 and 103)
Entry 120 |
10 |
The compound according to claim 1 which is 40-O-(3-hydroxyethyl)-rapamycin.
|
Invalid (101 and 103)
Entry 120 |
-
Infringement
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
0.25 mg0.5mg0.75 mg dosage strength everolimus tabletseverolimus tablets 0.25 mgeverolimus tablets 0.5 mgeverolimus tablets 0.75 mg dosage strengths | US 6,239,124 B1 |
7
|
Infringement
Entry 120Entry 169 |
everolimus tablets 0.25 mgeverolimus tablets 0.5 mgeverolimus tablets 0.75 mg dosage strengths | US 6,455,518 B2 |
7
|
Infringement
Entry 169
|